1Feikin DR, Sehuehat A, Kolezak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995 - 1997. Am J Public Health. 2000, 90(2) : 223 -229.
3Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases society of america/american thoracic society consensus guidelines on the management of community - scquired pneumonia in adults. Clin Infect Dis, 2007, 44(Suppl 2) : S27 -S71.
5Niederman MS, Feldman C, Richards GA. Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds. Eur Respir J, 2006, 27 ( 1 ) : 9 - 11.
6Capelastegui A, Espana PP, Quintana JM, et al. Validation of a predictive rule for the management of community - acquired pneumonia. Eur Respir J, 2006, 27 ( 1 ) : 151 - 157.
7Boussekey N, Leroy O, Alfandari S, et al. Proealeitonin kinetics in the prognosis of severe community - acquired pneumonia. Intensive Care Med, 2006, 32(3) : 469 -472.
8Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infection. Clin Infect Dis, 2005, 40 (9) : 1288 -1297.
9Deresinski S. Methicillin- resistant staphylococcus anreus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis, 2005, 40(4): 562-573.
10Scalera NM, File TM Jr. How long should we treat community - acquired pneumonia? Curr Opin Infect Dis, 2007, 20(2) : 177 - 181.
3Ngeow YF,Suwanjutha S,Chantarojanasriri T,et al.An asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia.Int J Infect Dis,2005,9:144-153.
4Lepow ML,Balassanian N,Emmerich J,et al.Interrelationships of viral,mycoplasmal,and bacterial agents in uncomplicated pneumonia.Am Rev Respir Dis,1968,97:533-545.
5Lim WS,Macfarlane JT,Boswell TC,et al.Study of community acquired pneumonia aetiology(SCAPA) in adults admitted to hospital:implications for management guidelines.Thorax,2001,56:296-301.
6Niederman MS,Mandell LA,Anzueto A,et al.Guidelines for the management of adults with community-acquired pneumonia.Diagnosis,assessment of severity,antimicrobial therapy,and prevention.Am J Respir Crit Care Med,2001,163:1730-1754.
7Heffelfinger JD,Dowell SF,Jorgensen JH,et al.Management of community-acquired pneumonia in the era of pneumococcal resistance:a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.Arch Intern Med,2000,160:1399-1408.
8Ngeow YF,Suwanjutha S,Chantarojanasriri T,et al.An Asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia.Int J Infect Dis,2005,9:144-153.
10Ostrosky-Zeichner L,Alexander BD,Kett DH,et al.Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans.Clin Infect Dis,2005,41:654-659.
